English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Mesenchymal stem cells (MSCs) therapy has become widely used to treat degenerative diseases. There are various tissue specific sources of stem cells with different therapeutic applications, therefore it is necessary to further investigate the characteristics and differences between MSCs from different origins, their potential and limitations. Osteoarthritis is the most common joint disease affecting both human and horses, and current treatment options have strong limitations. The use of MSCs to treat degenerative osteo-articular diseases has proven to be effective but further studies are needed to establish the safest and most effective protocol with regard to source, allogenic versus autologous cells and dose. Horses can be used as a large animal model for in vivo testing, due to some joint structural similarities. In the current study we compared the characteristics of synovial fluid-derived mesenchymal stem cells (SF-MSCs) harvested from horses with different joints degenerative diseases, to those observed in injured human joints. The results of this study showed that SF-MSCs from injured horse joints have substantial chondrogenic potential and they show great similarities to those observed in humans.

EQUESTRIAN SYNOVIAL FLUID MESENCHYMAL STEM CELLS, A POTENTIAL EXPERIMENTAL MODEL FOR OSTEOARTICULAR THERAPIES